Analysis of the digital medical originator model to explore the development prospect of digital medical care in China
FellowData explored China's future development opportunities in the digital healthcare field through an in-depth analysis of the shape and profit model of digital healthcare in the United States. Not only has the policy market expanded, but the profit model of insurance bills, drug companies, and patient fees has become clearer.
The US medical marketization system is helping digital healthcare
The degree of privatization in the United States has greatly promoted the development of third-party service providers. In 2015, there were more than 100 companies in the US digital medical field, and many companies made small products. They don't need to worry about channels and competition. Selling small products to large companies can be good.
At present, the digital medical segment in the United States has the following forms:
The medical marketization system in the United States has made digital medical care not so limited in the development process. The above segments have been developed more maturely and have realized multiple profit models.
Let's take a look at the profit models of several representative companies:
.jpg)
China still has many problems in the field of digital medical care
Medical resources: Doctor resources are scarce resources in China. Coupled with the unreasonable distribution of medical resources, patients tend to get together and doctors are too busy.
Medical system: China's medical system is owned by the government, and it is difficult for doctors to leave the hospital.
Medical insurance system: China's medical insurance system is not perfect, it is normal to look down on the disease.
Medical data: Lack of privacy protection, the medical data system has not been established.
Traditional concept: If you are sick, go to the hospital, hospitals must choose the top three hospitals, doctors should choose expert doctors.
Overcoming the above difficulties, China's digital health care has many opportunities to explore, both in terms of form and profit model.
Tetanus Shot,Tetanus Vaccine,Hepatitis B Injection,Hep B Vaccine
FOSHAN PHARMA CO., LTD. , https://www.full-pharma.com